JP2021500028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500028A5 JP2021500028A5 JP2020522004A JP2020522004A JP2021500028A5 JP 2021500028 A5 JP2021500028 A5 JP 2021500028A5 JP 2020522004 A JP2020522004 A JP 2020522004A JP 2020522004 A JP2020522004 A JP 2020522004A JP 2021500028 A5 JP2021500028 A5 JP 2021500028A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence represented
- represented
- antibody
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 43
- 125000003275 alpha amino acid group Chemical group 0.000 claims 35
- 108091026890 Coding region Proteins 0.000 claims 30
- 238000000034 method Methods 0.000 claims 25
- 239000002773 nucleotide Substances 0.000 claims 22
- 125000003729 nucleotide group Chemical group 0.000 claims 22
- 210000003719 b-lymphocyte Anatomy 0.000 claims 21
- 241000700605 Viruses Species 0.000 claims 12
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108020005004 Guide RNA Proteins 0.000 claims 5
- 230000002068 genetic effect Effects 0.000 claims 5
- 206010022000 influenza Diseases 0.000 claims 4
- 101710163270 Nuclease Proteins 0.000 claims 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000003390 tumor necrosis factor Human genes 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims 2
- 201000005702 Pertussis Diseases 0.000 claims 2
- 230000036436 anti-hiv Effects 0.000 claims 2
- 230000002924 anti-infective effect Effects 0.000 claims 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims 2
- 230000003097 anti-respiratory effect Effects 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 210000001806 memory b lymphocyte Anatomy 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 238000002255 vaccination Methods 0.000 claims 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 231100000699 Bacterial toxin Toxicity 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 208000001490 Dengue Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 206010054094 Tumour necrosis Diseases 0.000 claims 1
- 229950004283 actoxumab Drugs 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001512 anti-cytomegaloviral effect Effects 0.000 claims 1
- 230000003622 anti-hsv Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000000688 bacterial toxin Substances 0.000 claims 1
- 229950008086 bezlotoxumab Drugs 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 229960003115 certolizumab pegol Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 208000025729 dengue disease Diseases 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 238000010362 genome editing Methods 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229960000402 palivizumab Drugs 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023190846A JP7650336B2 (ja) | 2017-10-20 | 2023-11-08 | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 |
| JP2025038002A JP2025090718A (ja) | 2017-10-20 | 2025-03-11 | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762575275P | 2017-10-20 | 2017-10-20 | |
| US62/575,275 | 2017-10-20 | ||
| US201762580303P | 2017-11-01 | 2017-11-01 | |
| US62/580,303 | 2017-11-01 | ||
| US201862623371P | 2018-01-29 | 2018-01-29 | |
| US62/623,371 | 2018-01-29 | ||
| PCT/US2018/056789 WO2019079772A1 (en) | 2017-10-20 | 2018-10-19 | SYSTEMS AND METHODS FOR GENETICALLY MODIFIED B-LYMPHOCYTES FOR EXPRESSING SELECTED ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023190846A Division JP7650336B2 (ja) | 2017-10-20 | 2023-11-08 | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500028A JP2021500028A (ja) | 2021-01-07 |
| JP2021500028A5 true JP2021500028A5 (enExample) | 2021-11-25 |
| JP7383607B2 JP7383607B2 (ja) | 2023-11-20 |
Family
ID=66174267
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020522004A Active JP7383607B2 (ja) | 2017-10-20 | 2018-10-19 | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 |
| JP2023190846A Active JP7650336B2 (ja) | 2017-10-20 | 2023-11-08 | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 |
| JP2025038002A Pending JP2025090718A (ja) | 2017-10-20 | 2025-03-11 | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023190846A Active JP7650336B2 (ja) | 2017-10-20 | 2023-11-08 | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 |
| JP2025038002A Pending JP2025090718A (ja) | 2017-10-20 | 2025-03-11 | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11578118B2 (enExample) |
| EP (1) | EP3697895A4 (enExample) |
| JP (3) | JP7383607B2 (enExample) |
| KR (2) | KR20240156649A (enExample) |
| CN (2) | CN111479916B (enExample) |
| AU (2) | AU2018351072B9 (enExample) |
| BR (1) | BR112020007823A2 (enExample) |
| CA (1) | CA3079681A1 (enExample) |
| IL (1) | IL274082B1 (enExample) |
| MX (1) | MX2020004063A (enExample) |
| SG (1) | SG11202003024WA (enExample) |
| WO (1) | WO2019079772A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108486125B (zh) * | 2018-03-27 | 2024-01-05 | 重庆金迈博生物科技有限公司 | 一种核酸分子及其在制备人源单域抗体中的应用 |
| EP3844290A4 (en) * | 2018-09-13 | 2022-07-06 | Ramot at Tel-Aviv University Ltd. | GENETIC MODIFICATION OF B-LYMPHOCYTE RECEPTORS AND THEIR USES IN ANTIGEN-INDUCED ANTIBODY SECRETION |
| CN111995674B (zh) * | 2020-09-03 | 2022-02-11 | 中国人民解放军军事科学院军事医学研究院 | 抗COVID-19病毒中和抗体mhC3及其人源化抗体与应用 |
| WO2023192936A2 (en) * | 2022-03-30 | 2023-10-05 | Fred Hutchinson Cancer Center | Systems and methods to produce b cells that express selected antibodies and gene products |
| AU2023269134A1 (en) * | 2022-05-09 | 2024-12-12 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
| WO2025096483A2 (en) * | 2023-10-30 | 2025-05-08 | Be Biopharma, Inc. | Engineered cell preparations |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020102257A1 (en) | 1998-09-21 | 2002-08-01 | Leslie Sid Johnson | Human-murine chimeric antibodies against respiratory syncytial virus |
| US5604090A (en) | 1994-06-06 | 1997-02-18 | Fred Hutchinson Cancer Research Center | Method for increasing transduction of cells by adeno-associated virus vectors |
| US20010034062A1 (en) | 2000-02-09 | 2001-10-25 | Scott Koenig | Antibody gene therapy with adeno-associated viral vectors |
| EP1297168A2 (en) | 2000-07-03 | 2003-04-02 | Gala Design, Inc. | Expression vectors |
| AU7658101A (en) | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
| DE10113776B4 (de) * | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| US7696322B2 (en) * | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
| WO2006115800A2 (en) * | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| EA200802061A1 (ru) * | 2006-03-28 | 2009-04-28 | Байоджен Айдек Эмэй Инк. | Антитело или его фрагмент, специфично связывающееся с рецептором 1 инсулиноподобного фактора роста (igf-r1) (варианты), композиция на его основе, полинуклеотид, кодирующий вариабельную область антитела (варианты), содержащие полинуклеотид композиция (варианты) и вектор, содержащая вектор клетка-хозяин (варианты), способ продуцирования антитела или его фрагмента (варианты) и способ лечения гиперпролиферативного заболевания у животного организма |
| JP2012522520A (ja) | 2009-04-03 | 2012-09-27 | デューク ユニバーシティー | マウスモデル |
| PT2564695E (pt) * | 2009-07-08 | 2015-06-03 | Kymab Ltd | Modelos animais e moléculas terapêuticas |
| EP2470565A4 (en) | 2009-10-23 | 2013-12-11 | Garvan Inst Med Res | MODIFIED VARIABLE DOMAIN MOLECULES AND METHODS FOR PRODUCING AND USING THE SAME |
| US9074223B2 (en) * | 2010-01-08 | 2015-07-07 | Immusoft Corporation | Vectors and methods for transducing B cells |
| NZ703035A (en) | 2010-07-09 | 2016-06-24 | Crucell Holland Bv | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
| US8637035B2 (en) | 2010-07-16 | 2014-01-28 | Academia Sinica | Anti-dengue virus antibodies |
| EP2663334A4 (en) | 2011-01-10 | 2016-01-13 | Univ Emory | ANTIBODIES AGAINST INFLUENZA |
| PE20141521A1 (es) | 2011-08-23 | 2014-10-25 | Roche Glycart Ag | Moleculas biespecificas de union a antigeno activadoras de celulas t |
| GB201122047D0 (en) * | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| WO2013138691A1 (en) | 2012-03-16 | 2013-09-19 | University Of Rochester | Methods of predicting clinical outcome of chronic lymphocytic leukemia |
| WO2013148256A2 (en) * | 2012-03-27 | 2013-10-03 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the generation of immunoglobulin sequences |
| KR20230065381A (ko) | 2012-07-25 | 2023-05-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 유도 ｄｎａ 결합 단백질 및 게놈 교란 도구 및 이의 적용 |
| DK2921557T3 (en) | 2012-12-12 | 2016-11-07 | Broad Inst Inc | Design of systems, methods and optimized sequence manipulation guide compositions |
| EP4299741A3 (en) | 2012-12-12 | 2024-02-28 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| CN119752887A (zh) | 2012-12-12 | 2025-04-04 | 布罗德研究所有限公司 | 用于序列操纵的系统、方法和优化的指导组合物的工程化 |
| WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| CA2894668A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas systems and methods for altering expression of gene products in eukaryotic cells |
| WO2014093709A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| CN105209621B (zh) | 2012-12-12 | 2021-05-25 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| EP2931898B1 (en) | 2012-12-12 | 2016-03-09 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| US11332719B2 (en) | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
| US10993420B2 (en) * | 2013-03-15 | 2021-05-04 | Erasmus University Medical Center | Production of heavy chain only antibodies in transgenic mammals |
| ES2767318T3 (es) | 2013-06-17 | 2020-06-17 | Broad Inst Inc | Suministro, modificación y optimización de sistemas, métodos y composiciones para generar modelos y actuar sobre enfermedades y trastornos de células posmitóticas |
| CN105492611A (zh) | 2013-06-17 | 2016-04-13 | 布罗德研究所有限公司 | 用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物 |
| EP3011031B1 (en) | 2013-06-17 | 2020-09-30 | The Broad Institute Inc. | Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy |
| EP3011035B1 (en) | 2013-06-17 | 2020-05-13 | The Broad Institute, Inc. | Assay for quantitative evaluation of target site cleavage by one or more crispr-cas guide sequences |
| KR20160056869A (ko) | 2013-06-17 | 2016-05-20 | 더 브로드 인스티튜트, 인코퍼레이티드 | 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용 |
| WO2014204727A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
| DK3011029T3 (da) | 2013-06-17 | 2020-03-16 | Broad Inst Inc | Administration, modificering og optimering af tandem-guidesystemer, fremgangsmåder og sammensætninger til sekvensmanipulering |
| WO2015007903A1 (en) * | 2013-07-19 | 2015-01-22 | Vib Vzw | Targeted modified tnf family members |
| WO2015065964A1 (en) | 2013-10-28 | 2015-05-07 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof |
| CN106103705A (zh) | 2013-12-12 | 2016-11-09 | 布罗德研究所有限公司 | 核苷酸重复障碍中crispr‑cas系统的组合物和使用方法 |
| WO2015089419A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
| KR20160097327A (ko) | 2013-12-12 | 2016-08-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | 유전자 산물, 구조 정보 및 유도성 모듈형 ｃａｓ 효소의 발현의 변경을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 방법 |
| WO2015089486A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
| WO2015089473A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
| KR20250068794A (ko) | 2013-12-12 | 2025-05-16 | 더 브로드 인스티튜트, 인코퍼레이티드 | 게놈 편집을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 용도 및 치료적 응용 |
| CA2932479A1 (en) * | 2013-12-12 | 2015-06-18 | The Rockefeller University | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders |
| EP3102589A1 (en) * | 2014-02-04 | 2016-12-14 | Biogen MA Inc. | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| CN106459183B (zh) | 2014-03-31 | 2020-05-19 | 德克萨斯大学系统董事会 | 人源化百日咳抗体及其用途 |
| EP3230457B1 (en) | 2014-12-09 | 2021-06-30 | New York University | Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use |
| EP3277823B1 (en) * | 2015-04-03 | 2023-09-13 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| US12110490B2 (en) | 2015-12-18 | 2024-10-08 | The Broad Institute, Inc. | CRISPR enzymes and systems |
| JP6914274B2 (ja) | 2016-01-22 | 2021-08-04 | ザ・ブロード・インスティテュート・インコーポレイテッド | Ｃｒｉｓｐｒｃｐｆ１の結晶構造 |
-
2018
- 2018-10-19 IL IL274082A patent/IL274082B1/en unknown
- 2018-10-19 KR KR1020247035275A patent/KR20240156649A/ko active Pending
- 2018-10-19 SG SG11202003024WA patent/SG11202003024WA/en unknown
- 2018-10-19 BR BR112020007823-9A patent/BR112020007823A2/pt unknown
- 2018-10-19 WO PCT/US2018/056789 patent/WO2019079772A1/en not_active Ceased
- 2018-10-19 CA CA3079681A patent/CA3079681A1/en active Pending
- 2018-10-19 CN CN201880080021.5A patent/CN111479916B/zh active Active
- 2018-10-19 JP JP2020522004A patent/JP7383607B2/ja active Active
- 2018-10-19 AU AU2018351072A patent/AU2018351072B9/en active Active
- 2018-10-19 KR KR1020207014413A patent/KR102723182B1/ko active Active
- 2018-10-19 EP EP18869188.5A patent/EP3697895A4/en active Pending
- 2018-10-19 CN CN202411382074.6A patent/CN119265240A/zh active Pending
- 2018-10-19 MX MX2020004063A patent/MX2020004063A/es unknown
- 2018-10-19 US US16/757,707 patent/US11578118B2/en active Active
-
2023
- 2023-02-08 US US18/166,151 patent/US20230250159A1/en active Pending
- 2023-11-08 JP JP2023190846A patent/JP7650336B2/ja active Active
-
2024
- 2024-11-12 AU AU2024264571A patent/AU2024264571A1/en active Pending
-
2025
- 2025-03-11 JP JP2025038002A patent/JP2025090718A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500028A5 (enExample) | ||
| US20220363771A1 (en) | Multispecific antibodies | |
| EP3265575B1 (en) | Cd20 binding molecules and uses thereof | |
| KR20100034015A (ko) | 알레르기 질환 치료를 위한 방법 및 조성물 | |
| JP7650336B2 (ja) | 選択された抗体を発現するように遺伝子改変されたｂ細胞を産生するシステム及び方法 | |
| CN106573986A (zh) | 多特异性抗体 | |
| JP2022540083A (ja) | バイオフィルムを破壊するための抗体組成物 | |
| JP2024016201A5 (enExample) | ||
| CN115397852B (zh) | 工程化抗il-2抗体 | |
| TW201803981A (zh) | 用於以使用增強表現基因座爲基礎製造抗體之組成物及方法 | |
| JP2014515598A (ja) | 二重特異性三鎖抗体様分子 | |
| US20180237502A1 (en) | Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails | |
| CN113710688A (zh) | 用于治疗血液癌症和实体瘤癌症的嵌合抗原受体修饰的t细胞(car-t) | |
| JP2022185053A (ja) | 腸内消化に対する改善された安定性を有する抗体 | |
| EP4214229A1 (en) | Coronavirus antibodies and uses thereof | |
| JP2020529986A (ja) | Ｃｙｓ−ｍａｂのコンジュゲーション方法 | |
| CN109929033A (zh) | 一种特异性结合四种血清型登革病毒的人源抗体 | |
| CN101831434B (zh) | 抗人cd45ra鼠免疫球蛋白可变区基因及用途 | |
| CN101896502B (zh) | 抗人TNFα单抗、分子进化及其应用 | |
| CN103087155A (zh) | 一种狂犬病毒疫苗增效蛋白及编码该蛋白的基因和应用 | |
| WO2017156423A2 (en) | Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever | |
| EP3525813B1 (en) | Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop | |
| US12460010B2 (en) | Antibodies that bind TNFRSF25 | |
| RU2815823C2 (ru) | Выделенное биспецифическое антитело, которое специфически связывается с CD47 и PD-L1 | |
| EP4628095A1 (en) | Fusion protein and granulated antigen comprising same |